Shopping Cart 0
Cart Subtotal
USD 0

Bronchopulmonary-Dysplasia-Pipeline-Review-H2-2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Bronchopulmonary Dysplasia-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bronchopulmonary Dysplasia-Pipeline Review, H2 2017, provides an overview of the Bronchopulmonary Dysplasia (Respiratory) pipeline landscape.

Bronchopulmonary dysplasia is a form of chronic lung disease that develops in preterm neonates treated with oxygen and positive-pressure ventilation. Symptoms include tachypnea, tachycardia, increased respiratory effort (with retractions, nasal flaring, and grunting) and bluish skin color. The predisposing factors include congenital heart disease and severe respiratory or lung infection.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bronchopulmonary Dysplasia-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Bronchopulmonary Dysplasia (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bronchopulmonary Dysplasia (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Bronchopulmonary Dysplasia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 3, 10 and 1 respectively.

Bronchopulmonary Dysplasia (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Bronchopulmonary Dysplasia (Respiratory).

The pipeline guide reviews pipeline therapeutics for Bronchopulmonary Dysplasia (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Bronchopulmonary Dysplasia (Respiratory) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Bronchopulmonary Dysplasia (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Bronchopulmonary Dysplasia (Respiratory)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Bronchopulmonary Dysplasia (Respiratory).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Bronchopulmonary Dysplasia (Respiratory) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Bronchopulmonary Dysplasia-Overview

Bronchopulmonary Dysplasia-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Bronchopulmonary Dysplasia-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Bronchopulmonary Dysplasia-Companies Involved in Therapeutics Development

Chiesi Farmaceutici SpA

Insmed Inc

Martindale Pharmaceuticals Ltd

MediPost Co Ltd

Meridigen Biotech Co Ltd

Therabron Therapeutics Inc

Bronchopulmonary Dysplasia-Drug Profiles

AT-100-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

budesonide-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

caffeine citrate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CG-100-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs for Bronchopulmonary Dysplasia-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mecasermin rinfabate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Pneumostem-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

R-190-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

R-801-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

R-901-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

R-908-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

R-911-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Antagonize CD168 for Dermatology, Musculoskeletal, Oncology and Respiratory Disorders-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UMC-11901-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vitamin A palmitate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vitamin A palmitate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bronchopulmonary Dysplasia-Dormant Projects

Bronchopulmonary Dysplasia-Discontinued Products

Bronchopulmonary Dysplasia-Product Development Milestones

Featured News & Press Releases

Jun 02, 2016: Therabron Therapeutics Receives from FDA Rare Pediatric Disease Designation for Lead Phase 2 Program in Preterm Infants

May 25, 2016: Therabron Therapeutics Completes Enrollment of Phase 2 Clinical Trial for Lead Product Candidate CG100 for the Prevention of Chronic Lung Disease in Preterm Infants

May 03, 2016: MEDIPOST receives US Patent for 'PNEUMOSTEM' for Treating Lung Disease

Apr 28, 2016: Therabron Therapeutics Receives FDA Fast Track Designation for rhCC10 for the Prevention of Chronic Lung Disease Related to Premature Birth

Apr 13, 2016: Therabron Therapeutics Receives Notice of Allowance for New Patent Supporting the Recombinant CC10 Technology Platform

Mar 02, 2016: Therabron Therapeutics Announces New Study Aimed at the Creation of Multiple Novel Isoforms of the Company Lead Product Candidate

Dec 08, 2015: Therabron Therapeutics Announces Favorable Infant Outcomes with Six-Month Follow-Up of a Phase 1b Recombinant Human CC10 Clinical Trial

Oct 20, 2015: Therabron Therapeutics Receives Notice of Allowance for New EU Patent Supporting its Recombinant CC10 Technology Platform

Jul 21, 2015: Therabron Therapeutics Reaches 50 Percent Enrollment in Phase 2 Clinical Trial for Lead Pediatric Respiratory Critical Care Program

May 13, 2015: Therabron Therapeutics Secures New Orphan Designation for the Prevention of Bronchopulmonary Dysplasia

Sep 14, 2014: MediPost America clears Phase 1/2 IND for the U.S. clinical trial on stem cell drug for lung

Aug 12, 2014: MediPost, lung disease stem cell treatment drug 'Pneumostem' application for US clinical trial

Jul 29, 2014: Lung disease stem cell drug designated 'orphan drug in development stage'

Feb 06, 2014: Stem cells to treat lung disease in preterm infants

Sep 26, 2012: Medipost Receives KFDA Approval For Phase II Clinical Trial Of Lung Disease Medicine Pneumostem

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Bronchopulmonary Dysplasia, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Targets, H2 2017

Number of Products by Stage and Targets, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development for Bronchopulmonary Dysplasia, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Bronchopulmonary Dysplasia-Pipeline by Chiesi Farmaceutici SpA, H2 2017

Bronchopulmonary Dysplasia-Pipeline by Insmed Inc, H2 2017

Bronchopulmonary Dysplasia-Pipeline by Martindale Pharmaceuticals Ltd, H2 2017

Bronchopulmonary Dysplasia-Pipeline by MediPost Co Ltd, H2 2017

Bronchopulmonary Dysplasia-Pipeline by Meridigen Biotech Co Ltd, H2 2017

Bronchopulmonary Dysplasia-Pipeline by Therabron Therapeutics Inc, H2 2017

Bronchopulmonary Dysplasia-Dormant Projects, H2 2017

Bronchopulmonary Dysplasia-Discontinued Products, H2 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Bronchopulmonary Dysplasia Therapeutic Products under Development, Key Players in Bronchopulmonary Dysplasia Therapeutics, Bronchopulmonary Dysplasia Pipeline Overview, Bronchopulmonary Dysplasia Pipeline, Bronchopulmonary Dysplasia Pipeline Assessment


Companies

Chiesi Farmaceutici SpA

Insmed Inc

Martindale Pharmaceuticals Ltd

MediPost Co Ltd

Meridigen Biotech Co Ltd

Therabron Therapeutics Inc

Bronchopulmonary Dysplasia-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bronchopulmonary Dysplasia-Pipeline Review, H2 2017, provides an overview of the Bronchopulmonary Dysplasia (Respiratory) pipeline landscape.

Bronchopulmonary dysplasia is a form of chronic lung disease that develops in preterm neonates treated with oxygen and positive-pressure ventilation. Symptoms include tachypnea, tachycardia, increased respiratory effort (with retractions, nasal flaring, and grunting) and bluish skin color. The predisposing factors include congenital heart disease and severe respiratory or lung infection.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bronchopulmonary Dysplasia-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Bronchopulmonary Dysplasia (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bronchopulmonary Dysplasia (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Bronchopulmonary Dysplasia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 3, 10 and 1 respectively.

Bronchopulmonary Dysplasia (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Bronchopulmonary Dysplasia (Respiratory).

The pipeline guide reviews pipeline therapeutics for Bronchopulmonary Dysplasia (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Bronchopulmonary Dysplasia (Respiratory) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Bronchopulmonary Dysplasia (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Bronchopulmonary Dysplasia (Respiratory)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Bronchopulmonary Dysplasia (Respiratory).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Bronchopulmonary Dysplasia (Respiratory) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Bronchopulmonary Dysplasia-Overview

Bronchopulmonary Dysplasia-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Bronchopulmonary Dysplasia-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Bronchopulmonary Dysplasia-Companies Involved in Therapeutics Development

Chiesi Farmaceutici SpA

Insmed Inc

Martindale Pharmaceuticals Ltd

MediPost Co Ltd

Meridigen Biotech Co Ltd

Therabron Therapeutics Inc

Bronchopulmonary Dysplasia-Drug Profiles

AT-100-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

budesonide-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

caffeine citrate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CG-100-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs for Bronchopulmonary Dysplasia-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mecasermin rinfabate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Pneumostem-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

R-190-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

R-801-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

R-901-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

R-908-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

R-911-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Antagonize CD168 for Dermatology, Musculoskeletal, Oncology and Respiratory Disorders-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UMC-11901-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vitamin A palmitate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vitamin A palmitate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bronchopulmonary Dysplasia-Dormant Projects

Bronchopulmonary Dysplasia-Discontinued Products

Bronchopulmonary Dysplasia-Product Development Milestones

Featured News & Press Releases

Jun 02, 2016: Therabron Therapeutics Receives from FDA Rare Pediatric Disease Designation for Lead Phase 2 Program in Preterm Infants

May 25, 2016: Therabron Therapeutics Completes Enrollment of Phase 2 Clinical Trial for Lead Product Candidate CG100 for the Prevention of Chronic Lung Disease in Preterm Infants

May 03, 2016: MEDIPOST receives US Patent for 'PNEUMOSTEM' for Treating Lung Disease

Apr 28, 2016: Therabron Therapeutics Receives FDA Fast Track Designation for rhCC10 for the Prevention of Chronic Lung Disease Related to Premature Birth

Apr 13, 2016: Therabron Therapeutics Receives Notice of Allowance for New Patent Supporting the Recombinant CC10 Technology Platform

Mar 02, 2016: Therabron Therapeutics Announces New Study Aimed at the Creation of Multiple Novel Isoforms of the Company Lead Product Candidate

Dec 08, 2015: Therabron Therapeutics Announces Favorable Infant Outcomes with Six-Month Follow-Up of a Phase 1b Recombinant Human CC10 Clinical Trial

Oct 20, 2015: Therabron Therapeutics Receives Notice of Allowance for New EU Patent Supporting its Recombinant CC10 Technology Platform

Jul 21, 2015: Therabron Therapeutics Reaches 50 Percent Enrollment in Phase 2 Clinical Trial for Lead Pediatric Respiratory Critical Care Program

May 13, 2015: Therabron Therapeutics Secures New Orphan Designation for the Prevention of Bronchopulmonary Dysplasia

Sep 14, 2014: MediPost America clears Phase 1/2 IND for the U.S. clinical trial on stem cell drug for lung

Aug 12, 2014: MediPost, lung disease stem cell treatment drug 'Pneumostem' application for US clinical trial

Jul 29, 2014: Lung disease stem cell drug designated 'orphan drug in development stage'

Feb 06, 2014: Stem cells to treat lung disease in preterm infants

Sep 26, 2012: Medipost Receives KFDA Approval For Phase II Clinical Trial Of Lung Disease Medicine Pneumostem

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Bronchopulmonary Dysplasia, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Targets, H2 2017

Number of Products by Stage and Targets, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development for Bronchopulmonary Dysplasia, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Bronchopulmonary Dysplasia-Pipeline by Chiesi Farmaceutici SpA, H2 2017

Bronchopulmonary Dysplasia-Pipeline by Insmed Inc, H2 2017

Bronchopulmonary Dysplasia-Pipeline by Martindale Pharmaceuticals Ltd, H2 2017

Bronchopulmonary Dysplasia-Pipeline by MediPost Co Ltd, H2 2017

Bronchopulmonary Dysplasia-Pipeline by Meridigen Biotech Co Ltd, H2 2017

Bronchopulmonary Dysplasia-Pipeline by Therabron Therapeutics Inc, H2 2017

Bronchopulmonary Dysplasia-Dormant Projects, H2 2017

Bronchopulmonary Dysplasia-Discontinued Products, H2 2017

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Bronchopulmonary Dysplasia Therapeutic Products under Development, Key Players in Bronchopulmonary Dysplasia Therapeutics, Bronchopulmonary Dysplasia Pipeline Overview, Bronchopulmonary Dysplasia Pipeline, Bronchopulmonary Dysplasia Pipeline Assessment


Companies

Chiesi Farmaceutici SpA

Insmed Inc

Martindale Pharmaceuticals Ltd

MediPost Co Ltd

Meridigen Biotech Co Ltd

Therabron Therapeutics Inc